View More View Less
  • 1 Szegedi Tudományegyetem, Általános Orvostudományi Kar, Szeged, Korányi fasor 6., 6720
  • 2 Szegedi Tudományegyetem, Általános Orvostudományi Kar, Szeged
Open access

Absztrakt:

Az utóbbi évtizedekben elismertté vált a 18F-FDG-PET/CT nélkülözhetetlen szerepe a daganatos betegségek diagnosztikájában, stádiumbesorolásában és azok terápiára adott válaszának utánkövetésében. Ezen modern funkcionális és morfológiai képalkotást kombináló módszer használatának nemcsak onkológiai, hanem egyes kardiológiai kórképekben is vannak elfogadott evidenciái. Összefoglaló közleményünkben ismertetjük az optimalizált kardiológiai 18F-FDG-PET/CT vizsgálati protokollt és az ehhez szükséges beteg-előkészítés módszereit. Néhány esetben saját eredményekkel is illusztrálva áttekintjük az irodalmát a jól ismert „gold standard” myocardiumviabilitás és onkokardiológiai vizsgálatoknak, melyek mellett különös figyelmet fordítunk a szív gyulladásos megbetegedéseire. Ez a relatív újabb indikációs kör olyan betegségeket foglal magában, mint az infektív műbillentyű-endocarditis, cardialis implantált elektromos eszköz infekciója és a myocardium különböző eredetű gyulladásos megbetegedései, mint a sarcoidosis, amelyekben a 18F-FDG-PET/CT vizsgálatnak kitüntetett szerepe van, különösen a bizonytalan esetek differenciáldiagnosztikájában. Orv Hetil. 2019; 160(26): 1015–1024.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Jones T. The imaging science of positron emission tomography. Eur J Nucl Med Mol. 1996; 23: 807–813.

  • 2

    Jones T, Townsend D. History and future technical innovation in positron emission tomography. J Med Imaging (Bellingham) 2017; 4: 011013.

  • 3

    Chareonthaitawee P, Beanlands RS, Chen W, et al. Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Med. 2017; 58: 1341–1353.

  • 4

    Taegtmeyer H. Tracing cardiac metabolism in vivo: one substrate at a time. J Nucl Med. 2010; 51(Suppl 1): 80S–87S.

  • 5

    Harisankar CN, Mittal BR, Agrawal KL, et al. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake. J Nucl Cardiol. 2011; 18: 926–936.

  • 6

    Gormsen LC, Christensen NL, Bendstrup E, et al. Complete somatostatin-induced insulin suppression combined with heparin loading does not significantly suppress myocardial 18F-FDG uptake in patients with suspected cardiac sarcoidosis. J Nucl Cardiol. 2013; 20: 1108–1115.

  • 7

    Dilsizian V, Bacharach SL, Beanlands RS, et al. ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. J Nucl Cardiol. 2016; 23: 1187–1226.

  • 8

    Cerqueira MD, Weissman NJ, Dilsizian V, et al., American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Int J Cardiovasc Imaging 2002; 18: 539–542.

  • 9

    Patel H, Mazur W, Williams KA Sr, et al. Myocardial viability – state of the art: is it still relevant and how to best assess it with imaging? Trends Cardiovasc Med. 2018; 28: 24–37.

  • 10

    Anagnostopoulos C, Georgakopoulos A, Pianou N, et al. Assessment of myocardial perfusion and viability by positron emission tomography. Int J Cardiol. 2013; 167: 1737–1749.

  • 11

    Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011; 364: 1617–1625.

  • 12

    Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019; 40: 87–165.

  • 13

    Simor T. Cardiovascular MRI. In: Préda I, Czuriga I, Édes I, et al. (eds.) Cardiology. Foundations and guidelines. [Kardiovaszkuláris MRI. In: Préda I, Czuriga I, Édes I, et al. (szerk.) Kardiológia. Alapok és irányelvek.] Medicina Könyvkiadó, Budapest, 2010; pp. 117–143. [Hungarian]

  • 14

    McLean DS, Anadiotis AV, Lerakis S. Role of echocardiography in the assessment of myocardial viability. Am J Med Sci. 2009; 337: 349–354.

  • 15

    Kirschner R, Pécsvárady Z, Bedros JR, et al. Dobutamine stress cardiovascular magnetic resonance imaging in patients with peripheral artery disease. [Dobutaminterheléses szív mágneses rezonanciás vizsgálat alsó végtagi érszűkületben szenvedő betegeken.] Orv Hetil. 2011; 152: 285–291. [Hungarian]

  • 16

    Butany J, Nair V, Naseemuddin A, et al. Cardiac tumours: diagnosis and management. Lancet Oncol. 2005; 6: 219–228.

  • 17

    Bussani R, De-Giorgio F, Abbate A, et al. Cardiac metastases. J Clin Pathol. 2007; 60: 27–34.

  • 18

    Chiles C, Woodard PK, Gutierrez FR, et al. Metastatic involvement of the heart and pericardium: CT and MR imaging. Radiographics 2001; 21: 439–449.

  • 19

    Lichtenberger JP 3rd, Reynolds DA, Keung J, et al. Metastasis to the heart: a radiologic approach to diagnosis with pathologic correlation. Am J Roentgenol. 2016; 207: 764–772.

  • 20

    Kutyifa V, Merkely B, Pozsonyi Z, et al. Intracardiac echocardiography guided cardiac tumormass biopsy. [Intracardialis echokardiográfia-vezérelt cardialis tumormassza-biopszia.] Orv Hetil. 2008; 149: 1857–1859. [Hungarian]

  • 21

    Rahbar K, Seifarth H, Schäfers M, et al. Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT. J Nucl Med. 2012; 53: 856–863.

  • 22

    Nensa F, Tezgah E, Poeppel TD, et al. Integrated 18F-FDG PET/MR imaging in the assessment of cardiac masses: a pilot study. J Nucl Med. 2015; 56: 255–260.

  • 23

    Saponara M, Ambrosini V, Nannini M, et al. 18F-FDG-PET/CT imaging in cardiac tumors: illustrative clinical cases and review of the literature. Ther Adv Med Oncol. 2018; 10: 1758835918793569.

  • 24

    Lengyel M. Diagnosis, treatment and prevention of infective endocarditis. [Az infektív endocarditis diagnózisa, kezelése és prevenciója.] Orv Hetil. 2010; 151: 613–620. [Hungarian]

  • 25

    Saraste A, Knuuti J. Guidelines in review: comparison of ESC and AHA guidance for the diagnosis and management of infective endocarditis in adults. Are the differences clinically relevant? The European perspective. J Nucl Cardiol. 2019; 26: 309–312.

  • 26

    Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015; 36: 3075–3128.

  • 27

    Mahmood M, Kendi AT, Ajmal S, et al. Meta-analysis of 18F-FDG PET/CT in the diagnosis of infective endocarditis. J Nucl Cardiol. 2019; 26: 922–935.

  • 28

    Saby L, Laas O, Habib G, et al. Positron emission tomography/computed tomography for diagnosis of prosthetic valve endocarditis: increased valvular 18F-fluorodeoxyglucose uptake as a novel major criterion. J Am Coll Cardiol. 2013; 61: 2374–2382.

  • 29

    Maytin M, Jones SO, Epstein LM. Long-term mortality after transvenous lead extraction. Circ Arrhythm Electrophysiol. 2012; 5: 252–257.

  • 30

    Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm 2017; 14: e503–e551.

  • 31

    Bongiorni MG, Burri H, Deharo JC, et al. 2018 EHRA expert consensus statement on lead extraction: recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: endorsed by APHRS/HRS/LAHRS. Europace 2018; 20: 1217.

  • 32

    DeSimone DC, Sohail MR. Approach to diagnosis of cardiovascular implantable-electronic-device infection. J Clin Microbiol. 2018; 56: e01683–e01717.

  • 33

    Mahmood M, Kendi AT, Farid S, et al. Role of 18F-FDG PET/CT in the diagnosis of cardiovascular implantable electronic device infections: a meta-analysis. J Nucl Cardiol. 2019; 26: 958–970.

  • 34

    Erba PA, Lancellotti P, Vilacosta I, et al. Recommendations on nuclear and multimodality imaging in IE and CIED infections. Eur J Nucl Med Mol Imaging 2018; 45: 1795–1815.

  • 35

    Erdal BS, Clymer BD, Yildiz VO, et al. Unexpectedly high prevalence of sarcoidosis in a representative U.S. metropolitan population. Respir Med. 2012; 106: 893–899.

  • 36

    Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007; 357: 2153–2165.

  • 37

    Sejben I, Som Z, Cserni G. Sudden cardiac death due to sarcoidosis. [Hirtelen szívhalál sarcoidosis következtében.] Orv Hetil. 2017; 158: 1067–1070. [Hungarian]

  • 38

    Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11: 1305–1323.

  • 39

    Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease. A Scientific Statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J. 2007; 28: 3076–3093.

  • 40

    Kullmann T, Simor T, Tóth L, et al. New diagnostic methods of sarcoidosis in Hungary: labial biopsy and cardiac MRI. [Új lehetőségek a sarcoidosis diagnosztikájában Magyarországon: Ajakbiopszia és szív-MRI.] Orv Hetil. 2006; 147: 315–319. [Hungarian]

  • 41

    Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012; 53: 241–248.

  • 42

    Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014; 63: 329–336.

  • 43

    Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013; 34: 2636–2648.

  • 44

    Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J Am Coll Cardiol. 2009; 53: 1475–1487.

  • 45

    Lurz P, Luecke C, Eitel I, et al. Comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis: the MyoRacer-Trial. J Am Coll Cardiol. 2016; 67: 1800–1811.

  • 46

    Takano H, Nakagawa K, Ishio N, et al. Active myocarditis in a patient with chronic active Epstein–Barr virus infection. Int J Cardiol. 2008; 130: e11–e13.

  • 47

    Redureau E, Lairez O, Hitzel A, et al. Can positron emission tomography be useful to manage systemic sclerosis cardiac involvement? J Nucl Cardiol. 2017; 24: 1814–1815.

  • 48

    Besenyi Z, Ágoston G, Hemelein R, et al. Detection of myocardial inflammation by 18F-FDG-PET/CT in patients with systemic sclerosis without cardiac symptoms: a pilot study. Clin Exp Rheumatol. 2018 Dec 7. [Epub ahead of print]

  • 49

    Nensa F, Kloth J, Tezgah E, et al. Feasibility of FDG-PET in myocarditis: comparison to CMR using integrated PET/MRI. J Nucl Cardiol. 2018; 25: 785–794.